Immunoregulatory Factor Analysis in Platelet Rich Plasma (PRP) to Treat Knee Osteoarthritis (OA)

Overview

About this study

The purpose of this study is to investigate the correlation between a patient’s complete blood count with differential (CBC w/diff), platelet count, platelet-rich plasma (PRP) blood and platelet counts with a patient’s clinical outcome from a PRP injection for the treatment of knee osteoarthritis (OA).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

All patients aged 18-99 who are clinically identified by their physician as PRP injection candidates for knee OA will be included.  All patients who undergo PRP injection will be eligible for inclusion into the Regenerative Medicine Pilot Registry and Repository.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

John Tokish, M.D.

Open for enrollment

Contact information:

Miranda Hirschi RPSGT

(480) 342-1328

Hirschi.Miranda@mayo.edu

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer